This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rupnik, M.
Right arrow Articles by Barbut, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rupnik, M.
Right arrow Articles by Barbut, F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2008, p. 2146, Vol. 46, No. 6
0095-1137/08/$08.00+0     doi:10.1128/JCM.00598-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Clostridium difficile Toxinotype V, Ribotype 078, in Animals and Humans {triangledown}


arrow
LETTER
 
Two publications describing the important role of Clostridium difficile PCR ribotype 078 were published recently in the Journal of Clinical Microbiology. Keel and coworkers have described variability of C. difficile types isolated in animals and reported ribotype 078 to be most prevalent in isolates from swine (83%) and cattle (94%) (3). In a letter published a few months later, Goorhuis and coworkers corroborated this observation by detecting the same type in The Netherlands in a small number of strains isolated from pigs. They also showed ribotype 078 as the third most prevalent type in certain Dutch hospitals (2), a finding that was not observed in the study by Keel et al. Moreover, toxinotype V strains can include two ribotypes, 078 and 066. All ribotype 078 strains tested to date belong to toxinotype V, while ribotype 066 strains can belong to toxinotype V or VI.

We would like to point out two additional aspects. First, toxinotype V/ribotype 078 is indeed more often isolated from humans than could be concluded from Keel's paper. Data from the United States presented at the 2nd International Clostridium difficile Symposium in 2007 (B. M. Limbago et al., abstract book, p. 15; http://www.clostridia.net/IcdsAbstract%20Book.pdf) reported ribotype 078/toxinotype V to be the third most prevalent type in community-associated C. difficile disease. In the European prevalence study on hospital strains performed during a 2-month period in 2005, ribotype 078 was the 11th most prevalent type in Europe, representing 2.8% (9/322) of all toxigenic strains (1). Of all 14 countries involved (including also The Netherlands), ribotype 078 represented >10% of the strains only in Greece.

Additional data on C. difficile isolated from hospitalized patients in Germany and Switzerland suggest that toxinotype V/ribotype 078 is as common in both countries as reported by Goorhuis et al. (2). In Germany, where hospitals in Goettingen and the surrounding area were involved in the study, toxinotype V/ribotype 78 represented 7.3% of the strains in 2003 and 7.5% in 2006. In Switzerland (Basel), only a small selection of strains was analyzed in 2003 and 5 of 29 strains (17.2%) were toxinotype V. However, the percentage decreased to 9% in 2005 (9/100) and to 5.6% (5/88) in 2006. For these strains, the ribotype was not determined.

In France, data from the National Reference Laboratory for Clostridium difficile indicate that toxinotype V/ribotype 078 significantly increased in northern France from 3.25% (8/246) in July to December 2006 to 11.1% (16/144) in July to December 2007 (P = 0.001).

Second, toxinotype V/ribotype 078 is indeed the most prevalent type in several animal species worldwide (calves, pigs, horses). However, Canadian studies reported lower prevalence rates of ribotype 078 in calves (22.5%) (4). For European countries, data on typed strains are available for Slovenia, where we detected C. difficile in pigs, but only two of three farms were affected by toxinotype V/ribotype 066 (and not 078) while a third farm had toxinotype 0 (ribotype different from 078 but not identified).

In summary, toxinotype V/ribotype 078 seems to be well adapted to animal hosts. Depending on the geographic location, other subtypes of toxinotype V are associated with animals, particularly with piglets. In humans, this type is present at least from 2003 onward in different countries and its prevalence seems to be increasing.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 16 April 2008. Back


arrow
REFERENCES
 
    1
  1. Barbut, F., P. Mastrantonio, M. Delmée, J. S. Brazier, E. J. Kuijper, and I. R. Poxton on behalf of the European Study Group on Clostridium difficile (ESGCD). 2007. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin. Microbiol. Infect. 13:1048-1057.[CrossRef][Medline]
    2. 2
  2. Goorhuis, A., S. B. Debast, L. A. van Leengoed, C. Harmanus, D. W. Notermans, A. A. Bergwerff, and E. J. Kuijper. 2008. Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J. Clin. Microbiol. 46:1157-1158.[Free Full Text]
    3. 3
  3. Keel, K., J. S. Brazier, K. W. Post, S. Weese, and J. G. Songer. 2007. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J. Clin. Microbiol. 45:1963-1964.[Abstract/Free Full Text]
    4. 4
  4. Rodriguez-Palacios, A., H. R. Staempfli, T. Duffield, A. S. Peregrine, L. A. Trotz-Williams, L. G. Arroyo, and J. S. Brazier. 2006. Clostridium difficile PCR ribotypes in calves, Canada. Emerg. Infect. Dis. 12:1730-1736.[Medline]
Maja Rupnik*
Institute of Public Health Maribor
Centre for Microbiology
Prvomajska 1
2000 Maribor, Slovenia,0

Andreas Widmer
University of Basel Hospitals
Basel, Switzerland,1

Ortrud Zimmermann
University of Goettingen
Institute for Medical Microbiology
Goettingen, Germany,2

Catherine Eckert
Frédéric Barbut
National Reference Laboratory for Clostridium difficile
University Pierre et Marie Curie
Paris, France,3

* Phone: 386 2 4500 183
Fax: 386 2 4500 193
E-mail: maja.rupnik{at}zzv-mb.si

Journal of Clinical Microbiology, June 2008, p. 2146, Vol. 46, No. 6
0095-1137/08/$08.00+0     doi:10.1128/JCM.00598-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rupnik, M.
Right arrow Articles by Barbut, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rupnik, M.
Right arrow Articles by Barbut, F.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»